Sei Investments Co. Purchases 14,379 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Sei Investments Co. increased its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 7.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 197,806 shares of the biopharmaceutical company’s stock after acquiring an additional 14,379 shares during the period. Sei Investments Co.’s holdings in Intra-Cellular Therapies were worth $16,520,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its holdings in shares of Intra-Cellular Therapies by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock worth $1,878,000 after purchasing an additional 2,157 shares during the last quarter. Barclays PLC boosted its position in Intra-Cellular Therapies by 282.0% during the 3rd quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock worth $2,521,000 after buying an additional 25,435 shares during the period. Oak Ridge Investments LLC boosted its position in Intra-Cellular Therapies by 74.1% during the 4th quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock worth $1,656,000 after buying an additional 8,440 shares during the period. Principal Financial Group Inc. grew its holdings in Intra-Cellular Therapies by 3.3% during the 3rd quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company’s stock worth $43,735,000 after acquiring an additional 18,865 shares during the last quarter. Finally, Merit Financial Group LLC acquired a new position in Intra-Cellular Therapies in the 4th quarter valued at approximately $206,000. Institutional investors and hedge funds own 92.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Royal Bank of Canada reiterated a “sector perform” rating and set a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Piper Sandler reiterated a “neutral” rating and issued a $132.00 price target (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. StockNews.com began coverage on Intra-Cellular Therapies in a research report on Friday. They set a “hold” rating for the company. Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Finally, Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and increased their target price for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Ten research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $106.08.

Intra-Cellular Therapies Stock Up 0.0 %

NASDAQ:ITCI opened at $131.75 on Friday. Intra-Cellular Therapies, Inc. has a twelve month low of $64.09 and a twelve month high of $131.79. The company has a fifty day moving average of $129.00 and a 200-day moving average of $99.05. The firm has a market capitalization of $14.01 billion, a P/E ratio of -151.44 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. On average, analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.